结节病患者的静脉血栓栓塞长期风险:一项全国性队列研究
该研究利用丹麦全国登记数据,纳入1996-2020年新诊断结节病且既往无VTE的≥18岁患者14,742例,按年龄、性别和合并症1:4匹配背景人群58,968例。中位随访8.8年,结节病患者10年VTE绝对风险2.9% vs 背景人群1.6%(P<.0001),肺栓塞1.5% vs 0.7%(P<.0001),深静脉血栓1.6% vs 1.0%(P<.0001)。多变量Cox回归显示,结节病与诊断后第一年VTE风险升高相关(HR 4.94;95%CI 3.61-6.75),第一年后仍升高(HR 1.65;95%CI 1.45-1.87)。
要点
- 结节病患者诊断后第一年VTE风险显著升高:HR 4.94(95%CI 3.61-6.75),第一年后HR 1.65(95%CI 1.45-1.87)。
- 10年绝对风险:VTE 2.9% vs 1.6%(P<.0001),肺栓塞1.5% vs 0.7%(P<.0001),深静脉血栓1.6% vs 1.0%(P<.0001)。
- 排除癌症病史并删失随访期间新发癌症后,结节病与VTE的关联持续存在。
- 结节病患者发生VTE后3个月死亡率与无结节病的VTE患者无显著差异(校正HR 0.84;95%CI 0.61-1.15)。
适用人群与场景
- 丹麦全国登记中1996-2020年新诊断结节病、年龄≥18岁、既往无VTE的患者(两次及以上住院或门诊就诊)。
- 按年龄、性别和合并症1:4匹配的背景人群个体。
诊断标准与关键阈值
- 结节病诊断:两次及以上住院或门诊就诊记录。
- 主要结局:VTE(肺栓塞或深静脉血栓,及各自单独分析)。
研究设计与关键结果
- 研究类型:全国性队列研究;纳入结节病患者14,742例,匹配背景人群58,968例;中位年龄44.7岁,男性57.2%;中位随访8.8年。
- 10年绝对风险:VTE 2.9% vs 1.6%(P<.0001),肺栓塞1.5% vs 0.7%(P<.0001),深静脉血栓1.6% vs 1.0%(P<.0001)。
- 多变量Cox回归:诊断后第一年VTE的HR 4.94(95%CI 3.61-6.75),第一年后HR 1.65(95%CI 1.45-1.87)。
- 排除癌症病史并删失随访期间新发癌症后,关联持续存在。
- 结节病患者发生VTE后3个月死亡率与无结节病的VTE患者无显著差异(校正HR 0.84;95%CI 0.61-1.15)。
证据类型、等级与局限
- 证据类型:全国性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,结节病与匹配背景人群相比长期VTE风险更高;该结论基于观察性关联,原文未给出筛查或预防性抗凝建议。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Chronic inflammation is increasingly recognized as a risk factor for VTE, but unlike other inflammatory diseases including systemic lupus erythematosus and rheumatoid arthritis, data on the risk of VTE in patients with sarcoidosis are sparse.
RESEARCH QUESTION: Do patients with sarcoidosis have a higher long-term risk of VTE (pulmonary embolism or DVT, and each of these individually) compared with the background population?
STUDY DESIGN AND METHODS: Using Danish nationwide registries, patients aged ≥ 18 years with newly diagnosed sarcoidosis (two or more inpatient/outpatient visits, 1996-2020) without prior VTE were matched 1:4 by age, sex, and comorbidities with individuals from the background population. The primary outcome was VTE.
RESULTS: We included 14,742 patients with sarcoidosis and 58,968 matched individuals (median age, 44.7 years; 57.2% male). The median follow-up was 8.8 years. Absolute 10-year risks of outcomes for patients with sarcoidosis vs the background population were the following: VTE, 2.9% vs 1.6% (P < .0001), pulmonary embolism, 1.5% vs 0.7% (P < .0001), and DVT, 1.6% vs 1.0% (P < .0001), respectively. In multivariable Cox regression, sarcoidosis was associated with an increased rate of all outcomes in the first year after diagnosis (VTE: hazard ratio [HR], 4.94; 95% CI, 3.61-6.75) and after the first year (VTE: HR, 1.65; 95% CI, 1.45-1.87) compared with the background population. These associations persisted when excluding patients with a history of cancer and censoring patients with incident cancer during follow-up. Three-month mortality was not significantly different between patients with VTE with and without sarcoidosis (adjusted HR, 0.84; 95% CI, 0.61-1.15).
INTERPRETATION: In this nationwide cohort study, sarcoidosis was associated with a higher long-term risk of VTE compared with a matched background population.
参考来源
- Yafasova A, Fosbøl EL, Gustafsson F, et al. Long-Term Risk of VTE in Sarcoidosis: A Nationwide Cohort Study. Chest. 2024. PMID: 38295951. doi:10.1016/j.chest.2024.01.042
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。